Barclay Pharmaceuticals Laboratories’ Mental Health Business Unit is dedicated to addressing and managing complex mental health conditions, with a specialized focus on providing effective treatment solutions for patients suffering from schizophrenia and opioid addiction. This unit is committed to advancing care and improving the quality of life for individuals facing these challenging conditions. By leveraging innovative therapeutic approaches and research, they strive to offer comprehensive and tailored treatment options that meet the unique needs of each patient, contributing to better overall mental health outcomes.
Mental health
Addiction withdrawal
Our Lofexidine tablets, branded as Britlofex, provide a unique approach to treating opioid addiction by targeting the withdrawal and detoxification phase, rather than relying on long-term harm reduction methods like prescribed maintenance therapies. Unlike traditional treatment options, which often focus on managing addiction over an extended period, Britlofex emphasizes short-term intervention to support patients through the challenging withdrawal process.
Typically, the withdrawal period when using Lofexidine lasts less than 14 days. During this time, Lofexidine plays a crucial role in alleviating the intensity of withdrawal symptoms that are commonly experienced when detoxing from both heroin and opiate-based prescription medications. By easing these symptoms, Lofexidine facilitates a smoother and more manageable detoxification experience, allowing individuals to transition away from opioid dependence with reduced discomfort and a greater chance of long-term recovery success.
The withdrawal process typically takes less than 14 days, and Lofexidine can help with a reduction in the side-effects normally associated with detox from both heroin and opiate-based prescription pharmaceuticals.
Schizophrenia
Barclay Pharmaceuticals Laboratories offers a fully integrated web-based blood monitoring service, utilised by specialist mental health hospital pharmacies to enable dispensing decisions for our clozapine (Denzapine) therapy for treatment of resistant schizophrenia. In the US, all forms of Clozapine are similarly restricted on patient safety grounds.
Our Near Patient Testing (NPT) machines are installed in an increasing number of local medical facilities, helping to maintain patient well-being by allowing them access to their medication under the guidance of their trusted healthcare professionals in the community.
Barclay Pharmaceuticals Laboratories manages the process through our highly-trained monitoring team, dedicated to maximising patient safety while taking clozapine treatment.
withdrawal and detoxification instead of long-term harm reduction through prescribed maintenance therapy.
The withdrawal process typically takes less than 14 days, and Lofexidine can help with a reduction in the side-effects normally associated with detox from both heroin and opiate-based prescription pharmaceuticals.